Oxford BioDynamics - PDMR Dealing / Grant of Share Options
18 September 2026
Oxford BioDynamics Plc
("OBD" or the "Company")
PDMR Dealing / Grant of Share Options
Oxford BioDynamics Plc (AIM: OBD, the Company), the 3D Genomics Company, announces that it has today granted a total of 1,008,068,322 options (“Options”) over its ordinary shares of 0.1 pence each (“Ordinary Shares”), to Chief Executive Officer Richard Compton.
The options were granted under the Company’s 2016 Employee Share Option Plan with exercise prices and vesting dates as shown in the table below.
Number of options
Exercise price (p)
Premium over closing mid-market price on 17 September 2026
Vesting dates
336,022,774
0.115
-
12 equal tranches, one month to twelve months from today’s date
336,022,774
0.1725
50%
12 equal tranches, between 13 and 24 months from today’s date
336,022,774
0.23
100%
12 equal tranches, between 25 and 36 months from today’s date
Options will be exercisable at any time from 18 September 2027 upon vesting. Thereafter, the Options, once vested, will remain exercisable up to and including the tenth anniversary of the date of grant.
Following the grant of Options, Richard Compton’s interest in the Company will comprise:
Shareholding
Percentage of current issued share capital
Option of over Ordinary Shares
Percentage of current issued share capital
300,000,000
2.23%
1,008,068,322
7.50%
The notification below, made in accordance with the requirements of UK Market Abuse Regulation, provide further details:
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Richard Compton
2
Reason for the notification
a)
Position/status
Chief Executive Officer
b)
Initial notification/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Oxford BioDynamics Plc
b)
LEI
2138005Y1TK258O5U928
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of 0.1 pence each
ISIN: GB00BD5H8572
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
336,022,774 ordinary shares at an exercise price of 0.115 pence per share
336,022,774 ordinary shares at an exercise price of 0.1725 pence per share
336,022,774 ordinary shares at an exercise price of 0.23 pence per shared)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
18 September 2026
f)
Place of the transaction
Outside a trading venue
-Ends-
For further information please contact:
Oxford BioDynamics Plc +44 (0)1865 518910
Richard Compton, CEO
Paul Stockdale, CFO
Singer Capital Markets – Nominated Adviser and Broker
Alex Bond / Russell Cook / Anastassiya Eley
+44 (0)20 7496 3000
OAK Securities – Joint Broker
Matthew Clarke / Jerry Keen
+44 (0)20 3973 3678
Camarco – Financial PR
Marc Cohen / Sukaina Virji / Tilly Butcher / Fergus Young
+44 (0)20 3757 4980 / OBDFinancial@camarco.co.uk
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD), the 3D Genomics Company, is an international biotechnology company, advancing personalised healthcare through precision clinical diagnostic tests and EpiSwitch Orion, a cloud-based 3D genomics platform that transforms existing datasets into actionable insights for pharma and biotech partners.
Currently OBD has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.
The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch, which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.
The Company's recently launched proprietary AI predictive platform, EpiSwitch® Orion, makes the Company's knowledgebase and analytical tools available to researchers and partners, allowing them to generate insights into 3D regulatory biology from existing datasets. EpiSwitch Orion is a cloud-based 3D genomics platform that enables pharmaceutical partners to transform standard sequencing data - including legacy whole genome datasets - into actionable discovery insights in hours rather than months. By revealing the genome's 3D architecture, EpiSwitch Orion illuminates the 90-95% of disease-associated variants in non-coding regions that traditional NGS and GWAS approaches cannot decipher, bridging the gap between statistical associations and druggable therapeutic targets. The platform is supported by the world's largest curated 3D genomics knowledgebase, featuring over 1.5 billion data points and 15 million high-confidence genomic connections validated across 18,000+ patient samples in more than 40 diseases - a foundation built over nearly two decades that enables partners to identify targets, build predictive classifier models, and design precision interventions at unprecedented speed.
OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.
Since inception, the Company has participated in more than 40 collaborations with pharmaceutical and academic partners, including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma America, and has been awarded funding through the US Foundation for the National Institutes of Health's Partnership for Accelerating Cancer Therapies programme and the EU-funded HIPPOCRATES consortium in psoriatic arthritis.
The Company's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.
OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com, X (@OxBioDynamics) or LinkedIn.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHVDLFFQKLEBBK
Recent news on Oxford Biodynamics
See all newsBrief: Oxford Biodynamics Extends Vulpes Payment Deadline To October 30, 2026
Oxford BioDynamics - Extension of Timetable in relation to Placing
Oxford BioDynamics - PDMR Dealing / Grant of Share Options
Oxford BioDynamics - Holding(s) in Company
RCS - Oxford BioDynamics - Orion reveals link between five fatigue conditions